Small Cap Compass Therapeutics Shares Constructive Main Purpose Information From Pivotal Most cancers Drug Research For Biliary Tract Most cancers – Compass Therapeutics (NASDAQ:CMPX)

Compass Therapeutics, Inc. CMPX introduced statistically vital topline knowledge on Tuesday on the first efficacy endpoint for COMPANION-002, the corporate’s ongoing Part 2/3 trial of tovecimig (previously CTX-009) together with paclitaxel in sufferers with superior biliary tract most cancers (BTC).

Biliary tract most cancers is estimated to have an effect on roughly 23,000 sufferers yearly in america.

The research enrolled 168 grownup sufferers.

All sufferers had been dosed with 80 mg/m2 of paclitaxel on days 1, 8 and 15 of each 28-day cycle. Sufferers within the tovecimig arm had been additionally dosed with 10 mg/kg of tovecimig on days 1 and 15 of every 28-day cycle.

The topline outcomes present:

• In sufferers with BTC within the second-line setting, tovecimig together with paclitaxel (19 of 111 sufferers) had a 17.1% total response charge (ORR), together with one full response, in comparison with 5.3% for paclitaxel alone (3 of 57 sufferers).
• This 11.8% relative enchancment in ORR for these receiving the mixture was statistically vital (p=0.031).
• The research additionally confirmed variations between remedy arms for different efficacy measures, together with progressive illness (PD) charges of 16.2% in sufferers on tovecimig mixed with paclitaxel versus 42.1% in sufferers on paclitaxel alone.

The COMPANION-002 research is ongoing and the information aren’t but mature for the secondary consequence measures (together with PFS, OS and DoR) analyses.

The pre-specified variety of occasions required to set off the analyses of the secondary endpoints, together with progression-free survival (PFS), total survival (OS), and length of response (DoR), has not but been met attributable to fewer of those occasions occurring than had been initially modeled. The corporate expects to report these endpoints in This autumn of 2025.

The security profile of tovecimig is in step with prior research. An impartial Information Monitoring Committee (DMC) has reviewed security knowledge at 4 separate (pre-specified) DMC conferences and, after every assembly, really useful the continuation of the research with out modification.

The corporate expects to report detailed security knowledge with the analyses of secondary endpoints in This autumn 2025.

Value Motion: CMPX inventory is up 14.7% at $2.18 on the final examine Tuesday

Learn Subsequent: